ANTI-MARC1 CLONE 1G13 ZOOMAB« RABBIT MONOCLONAL (C15-1669-323)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 1G13 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects MARC1. It targets an epitope within 16 amino acids from the internal region.

Immunogen

KLH-conjugated linear peptide corresponding to 16 amino acids from the internal region, cytoplasmic domain of human Mitochondrial amidoxime-reducing component 1 (MARC1).

Application

Quality Control Testing

Evaluated by Western Blotting in Human liver tissue lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected MARC1 in Human liver tissue lysate.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected MARC1 in Mouse liver and Rat liver tissue lysates.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected MARC1 in HepG2 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected MARC1 in human liver tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Target description

Mitochondrial amidoxime-reducing component 1 (UniProt: Q5VT66; also known as mARC1, Molybdenum cofactor sulfurase C-terminal domain-containing protein 1, MOSC domain-containing protein 1, Moco sulfurase C-terminal domain-containing protein 1) is encoded by the MTARC1 (also known as MARC1, MOSC1) gene (Gene ID: 64757) in human. MARC1 is a single-pass type II outer mitochondrial membrane protein that consists of a mitochondrial matrix domain (aa 2-20), a transmembrane domain (aa 21-40), and a cytoplasmic domain (aa 41-337). It catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. It is known to reduce a multitude of N-hydroxylated prodrugs, particularly amidoximes, leading to increased drug bioavailability. It is also reported to be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, thereby regulating endogenous nitric oxide levels and biosynthesis. It has two structural domains, the molybdenum cofactor(Moco) sulfurase C-terminal (MOSC) domain (aa 187-335) and the MOSC N-terminal region (aa 93-183), forming a cleft that accommodates Moco. The MOSC domain that contains a large seven-stranded mostly antiparallel beta-barrel, engages multiple interactions with Moco pterin ring and phosphate group, which allows for a tight coordination of Moco within the core of the enzyme. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Kubitza, C., et al. (2018). Proc. Natl. Acad. Sci. USA. 115(47); 11958-11963; Krompholz, N., et al. (2012). Chem. Res. Toxicol. 25(11); 2443-2450; Kotthaus, J., et al. (2011). Biochem. J. 433(2); 383-391).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

0.3 mg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.